original ) (raw )Comparative Pharmacodynamics of Gatifloxacin and Ciprofloxacin in an In Vitro Dynamic Model: Prediction of Equiefficient Doses and the Breakpoints of the Area under the Curve/MIC Ratio
Irene Lubenko
Antimicrobial Agents and Chemotherapy, 2000
View PDFchevron_right
Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships
Irene Lubenko
Diagnostic Microbiology and Infectious Disease, 2001
View PDFchevron_right
In vitro antibacterial effect of enrofloxacin determined by time-killing curves analysis
Nikolina Rusenova
Bulgarian Journal of Veterinary Medicine
View PDFchevron_right
Pharmacodynamics of Trovafloxacin and Levofloxacin against Bacteroides fragilis in an In Vitro Pharmacodynamic Model
Anh Nguyen Hoang
Antimicrobial Agents and Chemotherapy, 2002
View PDFchevron_right
Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against Gram-positive and Gram-negative bacteria
Inga Odenholt
Journal of Antimicrobial Chemotherapy, 2000
View PDFchevron_right
Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin
C. Rogers
Journal of Antimicrobial Chemotherapy, 2000
View PDFchevron_right
Concentration–response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model
Irene Lubenko
International Journal of Antimicrobial Agents, 2007
View PDFchevron_right
MIC-Based Interspecies Prediction of the Antimicrobial Effects of Ciprofloxacin on Bacteria of Different Susceptibilities in an In Vitro Dynamic Model
S. Zinner
Antimicrobial Agents and Chemotherapy, 1998
View PDFchevron_right
Trovafloxacin: In Vitro Activity and Comparison with Other Antibacterial Agents
Liliana Guelfand
Drugs, 1999
View PDFchevron_right
Comparative in vitro activity of trovafloxacin against Gram-negative and Gram-positive pathogens
Erdal Akalin
Clinical Microbiology and Infection, 1998
View PDFchevron_right
Contribution of Immunocompetence to the Antibacterial Activities of Ciprofloxacin and Moxifloxacin in an in Vitro Pharmacodynamic Model*
Axel Dalhoff
Infection Supplement, 2005
View PDFchevron_right
Comparative Pharmacodynamics of Three Newer Fluoroquinolones versus Six Strains of Staphylococci in an In Vitro Model under Aerobic and Anaerobic Conditions
L. Hovde , John Rotschafer
Antimicrobial Agents and Chemotherapy, 2002
View PDFchevron_right
Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system
kyle bryan
Antimicrobial Agents and Chemotherapy, 1993
View PDFchevron_right
Net Effect of Inoculum Size on Antimicrobial Action of Ampicillin-Sulbactam: Studies Using an In Vitro Dynamic Model
Daniele Saverino
Antimicrobial Agents and Chemotherapy, 2006
View PDFchevron_right
Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance
S. Zinner
Antimicrobial Agents and Chemotherapy, 1987
View PDFchevron_right
AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin
Irene Lubenko
View PDFchevron_right
In Vitro Activity of Trovafloxacin against Bacteroides fragilis in Mixed Culture with either Escherichia coli or a Vancomycin- Resistant Strain of Enterococcus faecium Determined by an Anaerobic Time-Kill Technique
Wil Goessens
Antimicrobial Agents and Chemotherapy, 2001
View PDFchevron_right
Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model
Kerry LaPlante
2004
View PDFchevron_right
Research Article Comparative Evaluation of Three In Vitro Techniques in the Interaction of Ampicillin and Ciprofloxacin
Chuwkwuemeka Nworu
2016
View PDFchevron_right
The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses
Kelly Simmons
Journal of Antimicrobial Chemotherapy, 2001
View PDFchevron_right
Effect of Ciprofloxacin on S. aureus and E. coli Growth in Presence of Vitamin C Using Cup Cut Diffusion Method
Journal of Pharmacy and Pharmacology
Journal of Pharmacy and Pharmacology 7 (2019) 473-484, 2019
View PDFchevron_right
Relationships of the Area under the Curve/MIC Ratio to Different Integral Endpoints of the Antimicrobial Effect: Gemifloxacin Pharmacodynamics in an In Vitro Dynamic Model
Irene Lubenko
Antimicrobial Agents and Chemotherapy, 2001
View PDFchevron_right
Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient …
S. Zinner
Journal of …, 2000
View PDFchevron_right
Pharmacokinetics of enrofloxacin in dogs with experimental staphylococcal infection
Stanislav Yanev
Bulgarian Journal of …, 2011
View PDFchevron_right
The effect of albumin globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli
nathan keller
Clinical Microbiology and Infection, 2000
View PDFchevron_right
Pharmacodynamic Evaluation of the Intracellular Activity of Antibiotics towards Pseudomonas aeruginosa PAO1 in a Model of THP-1 Human Monocytes
F. Bambeke
Antimicrobial Agents and Chemotherapy, 2013
View PDFchevron_right
Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers
Roger Echols
Antimicrobial Agents and Chemotherapy, 1993
View PDFchevron_right
The impact of the pre-treatment interval on antimicrobial efficacy in a biological model
Andreas Gerber
Journal of Antimicrobial Chemotherapy, 1993
View PDFchevron_right
Novel Pharmacokinetic-Pharmacodynamic Model for Prediction of Outcomes with an Extended-Release Formulation of Ciprofloxacin
Axel Dalhoff
Antimicrobial Agents and Chemotherapy, 2004
View PDFchevron_right
Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections
Mariepaule Mingeotleclercq
J Antimicrob Chemother, 2006
View PDFchevron_right
Mutant Prevention Concentration of Garenoxacin (BMS-284756) for Ciprofloxacin-Susceptible or Resistant Staphylococcus aureus
Xilin Zhao
Antimicrobial Agents and Chemotherapy, 2003
View PDFchevron_right
Bactericidal properties of moxifloxacin and post-antibiotic effect
Axel Dalhoff
Journal of Antimicrobial Chemotherapy
View PDFchevron_right
Comparative Study of Pharmacokinetics/ Pharmacodynamics of Ciprofloxacin between 400 mg Intravenously Every 8 h and 400 mg Intravenously Every 12 h in Patients with Gram Negative Bacilli Bacteremia
Phanvasri Saengsuwan
2010
View PDFchevron_right